{"title":"“心中的蘑菇”:1例幽门螺杆菌感染性心内膜炎病例报告。","authors":"Yunhan Mao, XinPei Liu, ChaoJi Zhang, Jun Zheng","doi":"10.3389/fcvm.2025.1643975","DOIUrl":null,"url":null,"abstract":"<p><p><i>Volvariella volvacea (V. volvacea)</i>, an edible mushroom, may act as a pathogenic agent causing invasive fungal infections (IFIs) in immunocompromised patients. We present a 38-year-old male with persistent high fever post-allo-HSCT. Plasma mNGS revealed rising <i>V. volvacea</i> DNA loads (1,137 copies/μl). Intravenous antifungal therapy was initiated upon the diagnosis of IFI. Transthoracic echocardiography showed a 4 × 1 cm left atrial vegetation, with enhanced CT confirming multiorgan septic emboli (brain and kidney). PET/CT revealed a left atrial vegetation originating from a right lung infectious lesion, spreading contiguously into the left atrium via the pulmonary vein. Urgent vegetation resection was performed, followed by continued intravenous antifungal treatment. At the 5-month follow-up, the patient was afebrile with negative mNGS, completely resolved pulmonary lesion, and an improved quality of life. This case highlights the potential value of surgical-targeted antifungal therapy for fungal endocarditis and suggests practical principles: including mNGS-guided diagnosis, urgent surgical excision, long-term optimized antifungal therapy, and regular follow-up surveillance of the residual infected lesion.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1643975"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477206/pdf/","citationCount":"0","resultStr":"{\"title\":\"\\\"Mushroom in the heart\\\": a <i>Volvariella volvacea</i> infective endocarditis case report.\",\"authors\":\"Yunhan Mao, XinPei Liu, ChaoJi Zhang, Jun Zheng\",\"doi\":\"10.3389/fcvm.2025.1643975\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Volvariella volvacea (V. volvacea)</i>, an edible mushroom, may act as a pathogenic agent causing invasive fungal infections (IFIs) in immunocompromised patients. We present a 38-year-old male with persistent high fever post-allo-HSCT. Plasma mNGS revealed rising <i>V. volvacea</i> DNA loads (1,137 copies/μl). Intravenous antifungal therapy was initiated upon the diagnosis of IFI. Transthoracic echocardiography showed a 4 × 1 cm left atrial vegetation, with enhanced CT confirming multiorgan septic emboli (brain and kidney). PET/CT revealed a left atrial vegetation originating from a right lung infectious lesion, spreading contiguously into the left atrium via the pulmonary vein. Urgent vegetation resection was performed, followed by continued intravenous antifungal treatment. At the 5-month follow-up, the patient was afebrile with negative mNGS, completely resolved pulmonary lesion, and an improved quality of life. This case highlights the potential value of surgical-targeted antifungal therapy for fungal endocarditis and suggests practical principles: including mNGS-guided diagnosis, urgent surgical excision, long-term optimized antifungal therapy, and regular follow-up surveillance of the residual infected lesion.</p>\",\"PeriodicalId\":12414,\"journal\":{\"name\":\"Frontiers in Cardiovascular Medicine\",\"volume\":\"12 \",\"pages\":\"1643975\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477206/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Cardiovascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fcvm.2025.1643975\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1643975","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
"Mushroom in the heart": a Volvariella volvacea infective endocarditis case report.
Volvariella volvacea (V. volvacea), an edible mushroom, may act as a pathogenic agent causing invasive fungal infections (IFIs) in immunocompromised patients. We present a 38-year-old male with persistent high fever post-allo-HSCT. Plasma mNGS revealed rising V. volvacea DNA loads (1,137 copies/μl). Intravenous antifungal therapy was initiated upon the diagnosis of IFI. Transthoracic echocardiography showed a 4 × 1 cm left atrial vegetation, with enhanced CT confirming multiorgan septic emboli (brain and kidney). PET/CT revealed a left atrial vegetation originating from a right lung infectious lesion, spreading contiguously into the left atrium via the pulmonary vein. Urgent vegetation resection was performed, followed by continued intravenous antifungal treatment. At the 5-month follow-up, the patient was afebrile with negative mNGS, completely resolved pulmonary lesion, and an improved quality of life. This case highlights the potential value of surgical-targeted antifungal therapy for fungal endocarditis and suggests practical principles: including mNGS-guided diagnosis, urgent surgical excision, long-term optimized antifungal therapy, and regular follow-up surveillance of the residual infected lesion.
期刊介绍:
Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers?
At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.